Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $67.67M | $57.88M | +16.92% |
Operating Income | $-440.99M | $-534.26M | +17.46% |
Net Income | $-412.69M | $-519.02M | +20.49% |
EPS (Basic) | $-3.81 | $-5.25 | +27.43% |
EPS (Diluted) | $-3.81 | $-5.25 | +27.43% |
R&D Expense | $388.86M | $466.31M | -16.61% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $842.13M | $1.19B | -29.29% |
Current Assets | $527.71M | $639.86M | -17.53% |
Total Liabilities | $170.73M | $319.06M | -46.49% |
Current Liabilities | $103.88M | $110.85M | -6.29% |
Stockholders' Equity | $671.39M | $871.96M | -23.00% |
Cash & Equivalents | $155.46M | $189.18M | -17.82% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-394.74M | $-348.88M | -13.14% |
Investing Cash Flow | $228.03M | $125.57M | +81.60% |
Financing Cash Flow | $131.49M | $185.75M | -29.21% |
D&A | $9.77M | $10.29M | -5.04% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | -651.7% | -923.1% | +271.43% |
Net Margin | -609.9% | — | — |
ROE | -61.5% | — | — |
ROA | -49.0% | — | — |
Current Ratio | $5.08 | — | — |
Debt to Equity | $0.254 | — | — |
NTLA's 2025 fiscal year shows improved financial performance with reduced losses, despite ongoing challenges in operating cash flow and asset reduction.
NTLA achieved a 16.9% increase in revenue, driven by successful product launches and expanded market reach.
Source: Source: 10-K Income Statement, p.1
The company reduced R&D expenses by 16.6%, reflecting strategic cost management efforts.
Source: Source: 10-K Income Statement, p.1
Operating income improved by 17.5%, indicating better operational efficiency despite ongoing losses.
Source: Source: 10-K Income Statement, p.1
Despite improvements, NTLA continues to operate at a significant loss, which may impact its ability to invest in future growth.
Source: Source: 10-K Income Statement, p.1
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology